Key Multiple System Atrophy Market Players:
- Biogen (U.S.)
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Roche (Switzerland)
- UCB (Belgium)
- Lundbeck (Denmark)
- Teva Pharmaceuticals (Israel)
- Novartis (Switzerland)
- AbbVie (U.S.)
- Merck KGaA (Germany)
- Sanofi (France)
- AstraZeneca (UK)
- Sun Pharma (India)
- CSL Limited (Australia)
- Samsung Bioepis (South Korea)
- Hikma Pharmaceuticals (UK)
- Pharmaniaga (Malaysia)
The international market is effectively fragmentated and united, with the presence of notable players, such as Biogen, catering to an estimated share of the market, followed by Roche, grabbing a considerable share. This has deliberately been possible with their focus on alpha-synuclein inhibitors and diagnostics. Besides, UCB and Lundbeck are also readily dominating the overall market with the offering of symptomatic care solutions, followed by Teva and Sun Pharma, prioritizing cost-effective generics. Meanwhile, government-specific partnerships, AI-based collaborations, emerging market extension, and biomarker-based research and development are other suitable drivers of the market.
Here is a list of key players operating in the MSA market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of the multiple system atrophy (MSA) market was over USD 150.1 million.
The market size for the multiple system atrophy (MSA) market is projected to reach USD 230.8 million by the end of 2035 expanding at a CAGR of 4.9% during the forecast period i.e., between 2026-2035.
The major players in the market are Biogen, Roche, UCB, Lundbeck, and others.
In terms of the treatment segment, the pharmacological segment is anticipated to garner the largest market share of 92.5% by 2035 and display lucrative growth opportunities during 2026-2035.
The market in North America is projected to hold the largest market share of 44.7% by the end of 2035 and provide more business opportunities in the future.
